Amy Hobeika

TL;DR: Production of the DEX vaccine was feasible and DEX therapy was well tolerated in patients with advanced NSCLC, and some patients experienced long term stability of disease and activation of immune effectors.

TL;DR: The results indicate the potential for combining Treg-cell depletion with anticancer vaccines to enhance tumor antigen-specific immune responses and the need to explore dose and schedule of Treg depletion strategies in optimizing vaccine efforts.

TL;DR: This review evaluates the currently used in vivo and in vitro methods of assessing T-cell number and function, including delayed-type hypersensitivity, tetramer analysis, ELISPOT, flow cytometry-based analysis of cytokine expression, and PCR-based detection of T- cell receptor gene usage or cytokine production.

TL;DR: It is demonstrated that the mode of secretion and trafficking can influence the immunogenicity of different human TAAs, and may explain the lack of immunogenicicity of non-mutated TAAs found in cancer patients, and suggested that exosomal targeting could enhance future anti-tumor vaccination protocols.

TL;DR: It is feasible and safe to administer mRNA-loaded DC loaded with CEA mRNA to patients with advanced malignancies, and evidence of an immunologic response was demonstrated in biopsies of DC injection sites and peripheral blood of selected patients.